10-Q: Relay Therapeutics Reports Q1 2025 Financial Results, Cites Progress in Clinical Programs

Relay Therapeutics announces its Q1 2025 financial results, highlighting progress in clinical trials and strategic program prioritization.

Summary

• Relay Therapeutics reported a net loss of $77.1 million for the three months ended March 31, 2025, compared to a net loss of $81.4 million for the same period in 2024.
• The company's revenue for Q1 2025 was $7.7 million, stemming from the Elevar Agreement, while Q1 2024 revenue was $10.0 million, related to the Genentech Agreement.
• Research and development expenses decreased to $73.8 million in Q1 2025 from $82.4 million in Q1 2024, attributed to strategic streamlining of the research organization.
• General and administrative expenses were $18.7 million for Q1 2025, a decrease from $19.8 million in Q1 2024.
• As of March 31, 2025, Relay Therapeutics had cash, cash equivalents, and investments totaling $710.4 million, projected to fund operations into 2029.
• The company is advancing RLY-2608 in clinical trials, including the ReDiscover Trial and the RLY-2608-201 clinical trial for vascular malformations.
• Genentech terminated the Genentech Agreement effective January 7, 2025, resulting in no further milestone or other payments.
• In December 2024, Relay Therapeutics entered into an exclusive global licensing agreement with Elevar Therapeutics for lirafugratinib (RLY-4008), receiving $7.7 million in upfront consideration.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, there is progress in clinical trials, cost management, and a solid cash position. The termination of the Genentech agreement is a setback, but the Elevar agreement provides some revenue.

Positives

• The net loss decreased from $81.4 million in Q1 2024 to $77.1 million in Q1 2025.
• The company has $710.4 million in cash, cash equivalents, and investments, which is expected to fund operations into 2029.
• The initiation of the global Phase 2 clinical trial for RLY-2608 in patients with PIK3CA-related overgrowth spectrum represents progress in clinical development.
• The Elevar Agreement provided $7.7 million in revenue during the quarter.

Negatives

• The company continues to operate at a loss, with a net loss of $77.1 million for Q1 2025.
• Revenue decreased from $10.0 million in Q1 2024 to $7.7 million in Q1 2025.
• The termination of the Genentech Agreement eliminates potential future milestone payments.

Risks

• The company has a limited operating history and has incurred net losses since inception.
• The company will need to raise substantial additional funding.
• The company faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully.
• The company relies on third parties to conduct clinical trials and manufacture product candidates.
• The company may not be able to obtain regulatory approvals for its product candidates.
• The company may not be able to commercialize its product candidates, even if approved.
• The company may not be able to protect its intellectual property rights.
• The company's stock price has been volatile and may continue to be volatile.
• The company's executive officers, directors, principal stockholders and their affiliates exercise significant control over the company.
• The company's ability to utilize its net operating loss carryforwards and certain other tax attributes may be limited.
• The company is subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations.
• The company's relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations.
• The company's internal information technology systems, or those of its third-party collaborators and/or partners, may fail or suffer cybersecurity breaches, loss or leakage of data and other disruptions.
• The company may be adversely affected by natural disasters or other unplanned events and its business continuity and disaster recovery plans may not adequately protect it from a serious disaster.

Future Outlook

Relay Therapeutics expects its existing cash, cash equivalents, and investments as of March 31, 2025 will enable it to fund its planned operating expenses and capital expenditures into 2029.

Industry Context

Relay Therapeutics operates in the competitive biopharmaceutical industry, focusing on precision medicine and utilizing computational and experimental technologies for drug discovery. The company faces competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide.

Comparison to Industry Standards

• Relay Therapeutics is a clinical-stage company, so it is not yet generating revenue from product sales like established pharmaceutical companies.
• Comparable companies in the clinical-stage oncology and genetic disease space include companies like Blueprint Medicines, Black Diamond Therapeutics, and Kinnate Biopharma.
• Relay's focus on precision medicine and structure-based drug design aligns with industry trends towards targeted therapies.
• The company's cash runway into 2029 is a positive indicator of financial stability compared to other companies that may require more frequent capital raises.

Legal Proceedings

• On December 18, 2024, David Hayes, an alleged Relay Therapeutics stockholder, filed a derivative complaint against certain of the company's directors and officers, alleging excessive compensation.
• The Derivative Complaint asserts claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets, and breach of fiduciary duty of disclosure.
• On January 24, 2025, Relay Therapeutics and the Defendants separately answered the complaint.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical progress impact shareholder value.
• Employees: The company's financial stability and strategic decisions affect job security and opportunities.
• Patients: The company's clinical development programs aim to provide new treatment options for various diseases.
• Collaborators: The company's partnerships with other companies, such as Elevar Therapeutics, impact the development and commercialization of product candidates.

Next Steps

• Continue clinical trials for RLY-2608, including the ReDiscover Trial and the RLY-2608-201 clinical trial.
• Advance preclinical programs for NRAS-selective inhibitor, RLY-8161, and non-inhibitory chaperone for Fabry disease.
• Seek additional licenses and/or collaborations for other product candidates.
• Manage expenses and maintain a strong cash position to fund operations into 2029.

Key Dates

Keywords

Relay Therapeutics, financial results, clinical trials, RLY-2608, lirafugratinib, Elevar Therapeutics, Genentech, net loss, revenue, research and development, PI3K inhibitor, FGFR2 inhibitor, precision medicine, oncology, genetic disease